Postoperative Risk of Transfusion After Reversal of Residual Neuromuscular Block With Sugammadex Versus Neostigmine: A Retrospective Cohort Study
Main findingResult — go to the resultOdds ratio 1.11 95% CI 0.97–1.26Authors' conclusion
There is no statistically significant nor clinically important difference in the risk of postoperative transfusion in patients receiving sugammadex or neostigmine.
Study context
- Population
- Adults having noncardiac surgery given sugammadex or neostigmine, May 2016 to December 2020surgeries in 29,062 patients
- Participants
- 33,903 adults
- Exposure
- Sugammadex vs neostigmine for reversal of residual NMB
- Sugammadexn = 4,581
- Neostigminen = 29,322reference
- Outcome
- Any postoperative transfusion of RBC, and/or FFP, and/or platelets
Methodological detailssingle-centre, propensity score weighting, Planned analysis of coagulation laboratory parameters not completed because of high amount of missing laboratory data
- Single-centre
- Propensity score weighting
- Planned analysis of coagulation laboratory parameters not completed because of high amount of missing laboratory data
Main finding
As reported in the abstract
Odds ratio
1.11
95% CI 0.97–1.26
P = 0.118
By group
Sugammadex vs Neostigmine
OR 1.11 (95% CI 0.97–1.26); P = 0.118
Observational data: associations, not effects.
Secondary outcomes
Postoperative transfusion, raw incidence (unweighted)
| Outcome | OR (98.33% CI) | P value | |
|---|---|---|---|
| Postoperative ICU admission | 1.33 (1.17–1.52) | P < 0.0001 | |
| 0.512Odds ratio (log scale) |
Duration of hospitalization and need for resurgery
- No difference
Original publication
Postoperative Risk of Transfusion After Reversal of Residual Neuromuscular Block With Sugammadex Versus Neostigmine: A Retrospective Cohort Study. Anesth Analg. Published 18 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →